ReviewProgress in retinal and eye research2026
Transcending genome-wide association studies to create useful multi-omic views of glaucoma.
Review in Progress in retinal and eye research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Glaucoma is a leading cause of irreversible blindness worldwide, characterized by progressive retinal ganglion cell loss and functional impairment. It is a clinically heterogeneous disease driven by complex, multilayered molecular mechanisms. High-throughput multi-omic technologies are catalyzing a shift toward integrated multi-omic strategies to define glaucoma trajectory and disentangle its pathophysiology. Genomic, transcriptomic, epigenomic, proteomic, metabolomic, lipidomic, microbiome, and phenomic data can help identify biomarkers, molecular endotypes, and pathways that shape glaucoma susceptibility and progression. In this review, we synthesize the current multi-omic landscape in glaucoma, evaluate the strengths and limitations of each modality, and highlight key challenges in integrative approaches. Lastly, we propose conceptual and methodological frameworks for leveraging multi-omics to define the full spectrum of glaucoma, with a focus on optic nerve integrity, mechanistic insights, and precision medicine, while remaining agnostic to evolving omics technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.